Comparing pictures of the 45-year-old boybander from 2022 to now seem to suggest he's taking a trendy GLP-1 agonist drug ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

The evolution of diabetes technologies has led to the expansion of automated insulin delivery for type 2 diabetes, continuous ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Renaissance Investment Management, an investment management company, released its Q1 2025 “Small Cap Growth Strategy” ...

Hims & Hers (HIMS) defends recovery with personalized healthcare adoption, GLP-1 partnerships, and profit growth. Click here ...

GLP-1 receptor agonists may significantly reduce the risk for cardiovascular events in patients with rheumatoid arthritis ...

Genetic factors may explain why some people don't lose weight even when following nutritious diets, although health improvements can still be seen regardless of weight changes.

Martin Vollmer, biopharma program manager at Agilent Technologies, spoke to LCGC International about the evolving importance of glucagon-like peptide-1 (GLP-1) therapeutics and the challenges they ...

At HLTH Europe 2025, experts warned that stigma, cost barriers, and lack of support are hindering the wider use of GLP-1s in ...

Telehealth geriatric assessment significantly improves short-term outcomes for older adults with advanced cancers … JAMA releases feeding guide for advanced dementia patients and families … Heart ...

Study comparing bariatric surgery to GLP-1 medications shows 24% total weight loss from surgery versus 4.7% from injectables, ...